DRP-104 was designed as a novel prodrug of the broad acting glutamine antagonist DON (6-Diazo-5-oxo-L-norleucine). DRP-104 is inert in its prodrug form, affords high levels of plasma and GI tissue stability, has high tumour cell permeability and preferential tumour vs. plasma/GI tissue distribution for DON. Also, it synergizes with immune checkpoint blockade [1]. A PhI trial should be open soon [2].

Refs:

1 https://cancerres.aacrjournals.org/content/80/16_Supplement/5607

2 https://clinicaltrials.gov/ct2/show/NCT04471415